Introducing the Reactome Research Spotlight!
In October 2022, Reactome introduced a new feature, the Reactome Research Spotlight. This monthly feature will highlight a recent standout publication that makes use of Reactome data or analysis tools in its research.
In our first spotlight, we feature the paper “Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy” by Good et al, published in September 2022 in Nature Medicine. This paper identifies expansion of regulatory T cells as a biomarker of resistance and toxicity after CD19-CAR therapy in patients with large B cell lymphoma. Differential gene expression and Reactome pathway enrichment analysis identified TReg development as one of the top enriched pathways in the TReg CD4+ CD57-Helios+ cell populations associated with post-therapy progression and decreased neurotoxicity.
Do you use Reactome data or tools in your research? Email us at This email address is being protected from spambots. You need JavaScript enabled to view it. to have your work highlighted in an upcoming Spotlight feature.
Follow us on Twitter! @reactome to stay up to date with new and updated pathways, feature updates and more.
